| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| May 11, 2026 | ±2.7% | -1.0% | over-priced |
| October 31, 2025 | ±1.7% | -3.5% | under-priced |
| August 1, 2025 | ±1.6% | -3.8% | under-priced |
| May 2, 2025 | ±1.9% | +1.1% | over-priced |
| October 30, 2024 | ±2.0% | +1.2% | over-priced |
| July 31, 2024 | ±2.8% | -0.8% | over-priced |
| May 1, 2024 | ±1.6% | -2.5% | under-priced |
| November 3, 2023 | ±2.6% | -0.7% | over-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q1 FY2026 | $1.93 | $6.0B | $745M |
| Q4 FY2025 | $2.20 | $7.2B | $849M |
| Q3 FY2025 | $2.22 | $6.1B | $859M |
| Q2 FY2025 | $2.29 | $6.0B | $884M |
Stryker Corporation (SYK) reports in 106 days, with the next report estimated for September 27, 2026. Across the last 8 reports, options priced an average ±2.1% earnings move while the stock actually moved 1.8% on average — the market has been roughly fair on SYK's earnings risk. Fundamentals into the print: EPS up 14.2% year-over-year, revenue up 2.6%. QuantLogix's live 5-factor engine currently reads SYK as a buy at 50/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →